Navigation Links
Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Date:11/18/2013

ducts as well as for the discovery and development of new products.  We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products.  In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. 

CONTACT: Amgen
Kristen Davis, 805-447-3008 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... PHILADELPHIA , October 1, 2014 ... plans to software invited to engage around the theme, ... 29-30     Elsevier ... information products and services, will host a gathering of ... discuss issues and trends impacting healthcare today and in ...
(Date:9/30/2014)... 30, 2014 Applying a well-known optical phenomenon ... Harvard University has demonstrated the ability to "paint" ... that holds promise for making future, flexible electronic ... sides of next-gen rocket ships and spacecraft with ... through oil in water, it becomes iridescent, revealing ...
(Date:9/30/2014)... Using a bio-mimicking analog of one of ... an international research team led by Alejandro Briseno ... a major step in developing long-sought polymer architecture ... for use in electronic devices. , Briseno, ... and others at Stanford University and Dresden University ...
(Date:9/30/2014)... 2014 Report Details Biosimilar drugs ... revenues Do you want to find sales potentials ... predictions for those biological drugs from 2014, helping ... financial data, R&D trends, opportunities and selling prospects. ... to 2024 at overall world market, therapeutic class, ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Taking thin films to the extreme 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... all over the globe. Most have a lot of ... about their relevant experiences and capabilities with upfront personalities. ... what is missing is the proof about who really ... management the staff and their true particulars. This information ...
... her series of entrepreneurial profiles, this week Teresa reviews ... was published by O'Reilly Press in 2004. , ,Nerds ... good thing. , ,The first essay in Hackers & ... junior high school cafeteria, mapping out lunch tables according to ...
... Children's Hospital announced on Tuesday that they have ... purchase the information system CardioIMS. The system will be ... which addresses the needs of children and adults with ... an in-depth study of the Center's administrative and clinical ...
Cached Biology Technology:Whats Hush-Hush Marketing? 2Whats Hush-Hush Marketing? 3Hackers & Painters: Big Ideas from the Computer Age 2Hackers & Painters: Big Ideas from the Computer Age 3Hackers & Painters: Big Ideas from the Computer Age 4Hackers & Painters: Big Ideas from the Computer Age 5Children's Hospital chooses Camtronics for cardiology IT system 2
(Date:9/30/2014)... environmental effects of moorland burning is published today in ... the aim of relieving tensions on both sides of ... (Effects of Moorland Burning on the Ecohydrology of River ... which is practised predominantly to support red grouse populations ... hydrology, peat chemistry and physical properties, river water chemistry ...
(Date:9/30/2014)... captured the popular attention of both children and aquarium ... sold as dehydrated eggs, these tiny brine shrimp readily ... tank of salt water. , Physicists, though, are ... shrimp vertically migrate in large groups in response to ... night and retreating deeper during the day. , Two ...
(Date:9/30/2014)... of Medicine reports positive results of a phase ... subset of lung cancer marked by rearrangement of the ... with advanced non-small cell lung cancer testing positive for ... with 3 complete responses and 33 partial responses. Median ... disease to resume its growth after being slowed by ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... 20, 2012   Cell Therapeutics, Inc. ("CTI") (NASDAQ and ... European Medicines Agency,s ("EMA") Committee for Medicinal Products for ... on CTI,s Marketing Authorization Application ("MAA") for Pixuvri in ... with the CHMP on the Summary of Product Characteristics ...
... of scientists has found one of the rarest and least ... was believed to be extinct or on the verge of ... of Primatology , confirms the continued existence of this endangered ... it was previously not known to exist. Miller,s Grizzled ...
... flow channels offer a chemically unique environment, which at first ... in the crust of the earth, through which water flows, ... And yet it is precisely this extreme environment, where ... root of all life: The multiplication of biomolecules (reproduction) and ...
Cached Biology News:Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February 2Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February 3'Extinct' monkey rediscovered in Borneo by new expedition 2Avalanche of reactions at the origin of life 2Avalanche of reactions at the origin of life 3
96 Well Plate UB, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
... Incubated Console Orbital Shakers combine high ... unequalled programming power. The patented ... the unit to run with heavy ... filtration system reduces contamination. The ...
...
... combine high durability and capacity with ... use. The patented triple-counterbalanced heavy-duty mechanism ... run at high speed with heavy, ... range is delivered with tight uniformity ...
Biology Products: